Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects
Launched by GEORGETOWN UNIVERSITY · Sep 25, 2019
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. S/he is above the age of 18
- • 2. S/he has the ability to read, speak and write English
- • 3. S/he has telephone access
- • 4. S/he is diabetic and willing to check blood sugar levels every day
- • 5. Hb A1c \>7%
- • 6. Possesses a glucometer
- Exclusion Criteria:
- • 1. Allergy to kombucha ingredients
- • 2. Drinks kombucha regularly (\>3time per week)
About Georgetown University
Georgetown University is a prestigious academic institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Georgetown University leverages its extensive resources and expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among multidisciplinary teams, emphasizing ethical practices and adherence to regulatory standards. With a focus on translating scientific discoveries into clinical applications, Georgetown University plays a vital role in enhancing patient care and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials